Beta Bionics, Inc. (BBNX) vs SpyGlass Pharma, Inc. Common Stock (SGP)
A side-by-side comparison of Beta Bionics, Inc. and SpyGlass Pharma, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBNX
Beta Bionics, Inc.
$18.53HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
SGP
SpyGlass Pharma, Inc. Common Stock
$25.13HealthcareDelayed quote: Oct 6, 2026, 12:59 PM EDT
Total return — BBNX vs SGP
growth of $100 · dividends reinvested · last 1yBBNX +44.9% (+44.9%/yr)SGP -3.1% (-3.1%/yr)BBNX compounded faster over this window
BBNX SGP
BBNX vs SGP: by the numbers
- •SGP is the larger company ($840M vs $834M market cap).
- •Both run net losses; SGP's is the smaller (0.00% vs -61.32% net margin).
Metrics side by side
Valuation
| Metric | BBNX | SGP |
|---|---|---|
| P/S ratio | 7.00 | N/A |
| P/B ratio | 3.25 | 3.62 |
Profitability
| Metric | BBNX | SGP |
|---|---|---|
| Gross margin | 58.31% | 0.00% |
| Operating margin | -69.75% | 0.00% |
| Net margin | -61.32% | 0.00% |
| ROE | -28.46% | -24.12% |
| ROIC | -31.17% | -26.54% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.